Floatz logo

ANTI-CD22/PBD ADC ADCT-602

Blasts 5 Percent or More of Bone Marrow Nucleated Cells

M.D. Anderson Cancer Centerantibody_drug_conjugatePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Blasts 5 Percent or More of Bone Marrow Nucleated Cells cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
University of Southern California
Phase 3BBB
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

ANTI-CD22/PBD ADC ADCT-602 is also rated in:

CD22 PositiveDormant
CCC
Indicative ·
48 / 100
View asset →
Philadelphia Chromosome PositiveDormant
CC
Indicative ·
47 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →